SAN DIEGO, April 13, 2015 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company
developing novel oncology and drug-delivery therapies, today
announced the appointment of Harry J.
Leonhardt, Esq., as senior vice president, general counsel
and chief compliance officer, reporting to Dr. Helen Torley, president and chief executive
officer.
Mr. Leonhardt brings more than 30 years of corporate legal,
intellectual property, compliance, business development and mergers
and acquisitions experience to Halozyme, with an extensive
background in the biotechnology sector. He most recently served as
senior vice president of Legal and Compliance, and corporate
secretary for Amylin Pharmaceuticals, a biotech company acquired by
Bristol Myers Squibb in 2012. At Halozyme, he will be responsible
for all legal, compliance and intellectual property matters.
"As Halozyme executes our drug development strategies and
prepares for the future commercialization of our oncology pipeline,
I am pleased to welcome a biotech veteran of Harry's caliber to our
management team," said Dr. Torley. "His experience will be
invaluable to our team and will help facilitate the continued
growth and success of our business."
Prior to joining Amylin, Mr. Leonhardt served as senior vice
president, general counsel and corporate secretary for Senomyx;
executive vice president of Business Development, general counsel
and corporate secretary at Genoptix, Inc.; and senior vice
president, general counsel and secretary for Nanogen, Inc. He also
held positions of increasing responsibility at Allergan, Inc.
including head of worldwide litigation and general counsel for
European Operations. Early in his career, Mr. Leonhardt was an
attorney at the Los Angeles office
of Lyon & Lyon where he represented a number of prominent
clients in the biotechnology and pharmaceutical industries. He
received his Bachelor of Science degree from the University of the Sciences in Philadelphia and his
Juris Doctorate from the University of
Southern California Law Center.
About Halozyme
Halozyme Therapeutics is a
biotechnology company focused on developing and commercializing
novel oncology therapies that target the tumor microenvironment.
Halozyme's lead proprietary program, our investigational drug
PEGPH20, applies a unique approach to targeting solid tumors,
allowing increased access of co-administered cancer drug therapies
to the tumor. PEGPH20 is currently in development for
metastatic pancreatic cancer and non-small cell lung cancer and has
potential across additional cancers in combination with different
types of cancer therapies. In addition to its proprietary product
portfolio, Halozyme has established value-driving partnerships with
leading pharmaceutical companies including Roche, Pfizer, Janssen
and Baxter for its drug delivery
platform, ENHANZE™, which enables biologics and small molecule
compounds that are currently administered intravenously to be
delivered subcutaneously. Halozyme is headquartered in San Diego. For more information on how we are
innovating, please visit our corporate website at
www.halozyme.com.
Safe Harbor Statement
In addition to historical
information, the statements set forth above include forward-looking
statements that involve risk and uncertainties that could cause
actual results to differ materially from those in the
forward-looking statements. The forward-looking statements are also
identified through use of the words "believe," "enable," "may,"
"will," "could," "intends," "estimate," "anticipate," "plan,"
"predict," "probable," "potential," "possible," "should,"
"continue," and other words of similar meaning. Actual results
could differ materially from the expectations contained in
forward-looking statements as a result of several factors,
including unexpected results or delays in development and
regulatory review, regulatory approval requirements, unexpected
adverse events, competitive conditions and the continuation of the
Halozyme-Janssen and other collaborations. These and other factors
that may result in differences are discussed in greater detail in
the company's Annual Report on Form 10-K filed with the Securities
and Exchange Commission on March 2,
2015.
Contact:
Schond Greenway
858-704-8352
ir@halozyme.com
Jim Mazzola
858-704-8122
ir@halozyme.com
Logo -
http://photos.prnewswire.com/prnh/20100302/LA63139LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/halozyme-therapeutics-appoints-harry-j-leonhardt-esq-as-senior-vice-president-general-counsel-and-chief-compliance-officer-300064530.html
SOURCE Halozyme Therapeutics, Inc.